Physician profile
Brian B Friedrich
NPI 1952455701
$1,229.61
in general payments reported to CMS, 2019-2025
17 companies · $77.89 in 2025
The $77.89 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $172 · 2021: $27.50 · 2022: $44.33 · 2024: $31.14 · 2025: $77.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.24 | 2019-2020 | |
| Lilly USA, LLC | $200.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $115.62 | 2019 | |
| Astellas Pharma US INC | $96.34 | 2019-2020 | |
| Ucb, INC. | $77.89 | 2025 | Fintepla |
| Sanofi-Aventis U.S. LLC | $72.73 | 2019-2020 | |
| Abbvie INC. | $71.83 | 2021-2022 | |
| Amgen INC. | $60.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.00 | 2019-2020 | |
| Allergan, INC. | $50.28 | 2019-2020 | |
| Gilead Sciences, INC. | $47.21 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $31.14 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $19.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.29 | 2019 | |
| Glaxosmithkline, LLC. | $18.59 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.90 | 2019 | |
| Merck Sharp & Dohme LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Friedrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.